We are live on ! Find out more
HALO icon

Halozyme

210 hedge funds and large institutions have $1.96B invested in Halozyme in 2019 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 72 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

174% more call options, than puts

Call options by funds: $13.8M | Put options by funds: $5.03M

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

4% more funds holding

Funds holding: 202210 (+8)

2.19% more ownership

Funds ownership: 84.26%86.45% (+2.2%)

7% less capital invested

Capital invested by funds: $2.1B → $1.96B (-$143M)

13% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 72

Holders
210
Holders Change
+8
Holders Change %
+3.96%
% of All Funds
4.61%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
30
Increased
63
Reduced
72
Closed
22
Calls
$13.8M
Puts
$5.03M
Net Calls
+$8.74M
Net Calls Change
-$6.08M

HALO Hedge Fund Activity: Q3 2019 in Review

210 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2019, worth a combined $1.96B — down 6.8% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HALO positions and 22 closed out — a net gain of 8 holders — while 63 added to existing stakes and 72 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $30.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.4M sold.

  • 210 institutional investors held Halozyme (HALO) as of Q3 2019, up from 202 in Q2 2019.
  • Funds reported $1.96B of Halozyme stock for Q3 2019, down 6.8% quarter-over-quarter.
  • 30 funds opened new Halozyme positions in Q3 2019 and 22 closed out, a net change of +8 holders.
  • The largest Halozyme buyer in Q3 2019 was William Blair Investment Management, an estimated $30.9M added.
  • The largest Halozyme seller in Q3 2019 was Point72 Asset Management, an estimated $20.4M sold.

Based on aggregated 13F filings for Q3 2019.